期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

RNA干扰技术在妇科恶性肿瘤中的应用进展 被引量：1

Advances in RNA Interference Technology for Malignant Gynecological Cancer Treatment
下载PDF
导出
摘要 RNA干扰(RNAi)是一种在动植物中广泛存在的通过双链RNA(dsRNA)分子在mRNA水平上诱导特异性序列基因沉默的过程。随着对RNAi研究的不断深入,其作用机制的逐步阐明,RNAi技术也日趋完善和成熟,作为一种新型研究工具已广泛应用于医学领域中,尤其在恶性肿瘤的研究中作用显著,有望成为攻克肿瘤、病毒性疾病及遗传性疾病的新手段。现就RNAi技术应用于妇科肿瘤的研究与治疗进行综述。 RNA interference（RNAi） is a post transportational gene silencing induced by introduction of double-strand RNA homologous to the target gene in animals and plants. With the deepening study of RNAi technology,its mechanism is being clarified gradually. RNAi technology is also becoming more perfect and mature. As a useful research technique, RNAi has been widely applied in the field of medicine, especially affects obviously in the field of malignant tumor research. It is a promising technique in fighting tumors, viral infection and inherited diseases. Here is to provide a review on the latest progress and the application of RNAi technology on gynecologic malignant tumor.
作者 曾智华 郑秀
机构地区 福建医科大学第一临床医学院妇产科
出处 《医学综述》 2011年第24期3720-3723,共4页 Medical Recapitulate
关键词 RNA干扰 宫颈癌 卵巢癌 子宫内膜癌 RNA interference Cervical cancer Ovarian cancer Endometrial cancer
分类号 R737.3 [医药卫生—肿瘤]
  • 相关文献

参考文献20

  • 1Fire A,Xu S,Montgomery MK,et al.Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans[J].Nature,1998,391(6669):806-811.
  • 2Kim VN.RNA interference in functionalgenomics and medicine[J].Korean Med Sci,2003,18(3):309-318.
  • 3Cheng JC,Moore TB,Sakamoto KM.RNA interference and human disease[J].Mol Genet Metab,2003,80(1/2):121-128.
  • 4Jemal A,Siegel R,Ward E,et al.Cancer statisties[J].CA Cancer J Clin,2008,58(2):71-96.
  • 5Andrawiss M.Cervical cancer vaccines available in 2007[J].Drug Discov Today,2005,10(14):949-950.
  • 6Medzhitov R,Hurlburt P,Janeway CA Jr.A human homologue of the Drosophila Toll protein signals activation of adaptiveimmunity[J].Nature,1997,388(6640):394-397.
  • 7Bousarghin L,Touze A,Gaud G,et al.Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs[J].Mol Cancer Ther,2009,8(2):357-365.
  • 8Kreis NN,Sanhaji M,Kramer A,et al.Restoration of the tumor suppressor p53 by downregulating cyclin B1 in human papillomavirus 16/18-infected cancer cells[J].Oncogene,2010,29(41):5591-5603.
  • 9Kawakami M,Nakamura T,Okamura N,et al.Knock-down of sorcin induces up-regulation of MDR1 in HeLa cells[J].Biol Pharm Bull,2007,30(6):1065-1073.
  • 10He M,Cheng Y,Li W,et al.Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade[J].BMC Cancer,2010,10:170.

二级参考文献7

  • 1Fang FM,Chien CY,Li CF,et al.Effect of S-phase kinaseassociated protein 2 expression on distant metastasis and survival in nasopharyngeal carcinoma patients.Int J Radiat Oncol Biol Phys,2009,73:202-207.
  • 2Bahnassy AA,Zekri AR,Saleh M,et al.The possible role of cell cycle regulators in multistep process of HPV-associated cervical carcinoma.BMC Clin Pathol,2007,7:4.
  • 3Kim JY,Lim SJ,Kim HJ,et al.Clinical significance of p27 and Skp2 protein expression in uterine cervical neoplasm.Int J Gynecol Pathol,2007,26:242-247.
  • 4Mizuma M,Katayose Y,Yamamoto K,et al.Up-regulated p27Kip1 reduces matrix metalloproteinase-9 and inhibits invasion of human breast cancer cells.Anticancer Res,2008,28:2669-2677.
  • 5Lindberg D,Akerstrom G,Westin G.Mutational analysis of p27 (CDKN1B) and p18 (CDKN2C) in sporadic pancreatic endocrine tumors argues against tumor-suppressor function.Neoplasia,2007,9:533-535.
  • 6Kawakami K,Enokida H,Tachiwada T,et al.Increased SKP2 and CKS1 gene expression contributes to the progression of human urothelial carcinoma.J Urol,2007,178:301-307.
  • 7Ravaioli A,Monti F,Regan MM,et al.p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer.Ann Oncol,2008,19:660-668.

共引文献3

同被引文献9

  • 1Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69.
  • 2Winter WE 3rd,Maxwell GL,Tian C,et al.Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer:a Gynecologic Oncology Group Study[J].J Clin Oncol,2008,26(1):83.
  • 3Tan FL,Yin JQ.Application of RNAi to cancer research and therapy[J].Front Biosci,2005,10(5):1946.
  • 4Janknecht R.On the road to immortality:hTERT upregulation in cancer cells[J].FEBS Lett,2004,564(1-2):9.
  • 5George J,Banik NL,Ray SK.Combination of hTERT knock-down and IFN-γtreatment inhibited angiogenesis and tumor progression in glioblastoma[J].Clin Cancer Res,2009,15(23):186.
  • 6Livak KJ,Schmittgen TD.Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T))method[J].Methods,2001,25(4):402.
  • 7Chan SR,Blackburn EH.Telomeres and telomerase[J].Phi-los Trans R Soc Lond B Biol Sci,2004,359:109.
  • 8Kyo S,Inoue M.Complex regulatory mechanisms of telomerase activity in normal and cancer cells:How can we apply them for cancer therapy[J].Oncogene,2002,21(4):688.
  • 9Indran IR,Hande MP,Pervaiz S.hTERT overexpression alle-viates intracellular ROS production,improves mitochondrial function,and inhibits ROS-mediated apoptosis in cancer cells[J].Cancer Res,2010,71(1):266.

引证文献1

二级引证文献1

医学综述
2011年 第24期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部